[go: up one dir, main page]

US20050267083A1 - Dosage form for hormonal contraception - Google Patents

Dosage form for hormonal contraception Download PDF

Info

Publication number
US20050267083A1
US20050267083A1 US11/009,817 US981704A US2005267083A1 US 20050267083 A1 US20050267083 A1 US 20050267083A1 US 981704 A US981704 A US 981704A US 2005267083 A1 US2005267083 A1 US 2005267083A1
Authority
US
United States
Prior art keywords
hormone
daily units
dosage form
folic acid
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/009,817
Inventor
Georg Schramm
Eric-Paul Paques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to GRUNENTHAL GMBH reassignment GRUNENTHAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PAQUES, ERIC-PAUL, SCHRAMM, GEORG
Priority to US11/244,974 priority Critical patent/US8580771B2/en
Publication of US20050267083A1 publication Critical patent/US20050267083A1/en
Priority to US13/070,205 priority patent/US20110172197A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Definitions

  • the present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for uninterrupted daily oral administration to women, characterised in that the hormone-containing daily units contain folic acid in a daily amount of at most 200 ⁇ g and the hormone-free daily units in each case contain folic acid in a daily amount of >200 ⁇ g up to the maximum permissible amount of folic acid for women.
  • the combination of hormonal contraceptives and folic acid is already known from WO 99/53910.
  • the amount of folic acid per daily dose of hormones merely matches the changes in a woman's folic acid requirements as she ages, and does not take account of the changes in folic acid requirements over a contraceptive-taking cycle.
  • the dosage form according to the invention for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for uninterrupted daily oral administration to women, characterised in that the hormone-containing daily units contain folic acid in a daily amount of at most 200 ⁇ g and the hormone-free daily units in each case contain folic acid in a daily amount of >200 ⁇ g up to the maximum permissible amount for women of folic acid.
  • hormone-containing daily units of the dosage form according to the invention may each comprise a daily amount of folic acid corresponding to this minimum effective daily amount of folic acid.
  • the hormone-containing daily units of the dosage form according to the invention contain 0 to 200 ⁇ g of folic acid, particularly preferably 5 to 200 ⁇ g of folic acid.
  • the hormone-containing daily units of the dosage form according to the invention may also not contain any additional folic acid, however.
  • the hormone-free daily units of the folic acid dosage form according to the invention contain folic acid in an amount of more than 200 ⁇ g up to the maximum permissible daily amount of folic acid for women, preferably up to 5 mg of folic acid per daily unit, particularly preferably of more than 200 ⁇ g to 5 mg folic acid, very particularly preferably up to the maximum permissible daily amount of folic acid for women of reproductive age.
  • folic acid By adding folic acid to the hormone-free daily units of the dosage form according to the invention in amounts of up to the maximum permissible amount, it is possible to increase the folic acid concentration in a woman's body while she is taking the hormone-free daily units to the extent that the her body's increased folic acid requirement is met as quickly as possible if she stops taking a hormone-containing contraceptive and then falls pregnant.
  • the hormone-containing daily units of the dosage form according to the invention preferably each contain the same amount of folic acid. This also applies to the hormone-free daily units, which likewise each contain the same amount of folic acid, this being greater than the amount contained in the hormone-containing daily units however.
  • the folic acid may also be present in the dosage form according to the invention as a pharmaceutically safe salt, preferably as sodium, potassium or magnesium salt, or as a corresponding derivative.
  • Suitable derivatives of folic acid are mono- or diesters, wherein the diesters may be differently or identically esterified.
  • Suitable ester groups are preferably C 1 -C 8 low alkyl groups, such as methyl, ethyl, propyl or butyl, branched C 1 -C 8 low alkyl groups, such as isopropyl, isobutyl or sec.-butyl, cycloalkyl groups, such as cyclopentyl or cyclohexyl, aryl groups, such as phenyl or substituted phenyl with 1-2 substituents, such as low alkyl or haloalkoxyl groups, or arylalkyl groups with C 1 -C 8 alkyl and aryl groups, such as phenyl or substituted phenyl.
  • hormone-free daily units and optionally the hormone-containing daily units may contain further vitamins or minerals in addition to the folic acid.
  • the number of daily units of a dosage form according to the invention may correspond to a natural, monthly menstrual cycle.
  • the dosage form according to the invention contains 21 to 25 hormone-containing daily units and 7 to 3 hormone-free daily units.
  • a dosage form according to the invention may contain hormone-containing daily units to be taken without interruption for up to 2 years, preferably up to 1 year, and 7 to 3 hormone-free daily units.
  • the dosage form according to the invention may comprise 42 to 52 or 77 to 193 hormone-containing daily units alongside 7 to 3 hormone-free daily units.
  • the hormone-containing daily units of the dosage form according to the invention may each contain at least one contraceptively acting hormone component, preferably a combination of hormone components such as an oestrogen and a gestagen.
  • Oestrogens which are suitable for the hormone-containing daily units of the dosage form according to the invention are preferably selected from the group comprising oestradiol, oestradiol valerate, ethinyloestradiol and mestranol. Ethinyloestradiol is particularly preferred as the oestrogen for the dosage form according to the invention.
  • Gestagens which are suitable for the hormone-containing daily units of the dosage form according to the invention are preferably selected from the group comprising norethisterone, norethisterone acetate, norethisterone enantate, norgestimate, norgestrel, levonorgestrel, gestodene, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, lynestrenol, cyproterone acetate, drospirenone, dienogest, desogestrel, progesterone, dydrogesterone, medrogestone, ethynodiol, promegestone, nomegestrol acetate and trimegestone.
  • Oestrogens Oestradiol, oestradiol valerate 0.5 to 4 mg Ethinyloestradiol 5 to 50 ⁇ g Mestranol 8 to 70 ⁇ g
  • Gestagens Norethisterone, norethisterone acetate 0.5 to 1.0 mg Norgestimate 0.1 to 0.25 mg Norgestrel 0.3 to 1.0 mg Levonorgestrel 0.05 to 0.15 mg Gestodene 0.05 to 0.12 mg Hydroxyprogesterone caproate 10 to 800 mg Medroxyprogesterone acetate 2.5 to 40 mg Megestrol acetate 1.0 to 10 mg Chlormadinone acetate 0.5 to 10 mg Lynestrenol 0.4 to 3 mg Cyproterone acetate 0.5 to 10 mg Drospirenone 1.0 to 10 mg Dienogest 1.0 to 10 mg Desogestrel 0.06 to 0.30 mg Progesterone 100 to 1000 mg Dydrogesterone 5 to 50 mg Medrogestone 2 to 30 mg Ethynodiol, ethynodiol diacetate 0.4 to 3 mg Promegestone 0.5 to 10 mg Nomegestrol acetate 0.5 to 10 mg Trimegestone 1
  • the dosage forms according to the invention especially the hormone-containing daily units, preferably comprise the following hormone combinations:
  • the dosage form according to the invention provides a multiphasic hormone combination
  • the hormone-containing daily units be taken without interruption only for a period of 21 to 25 days, followed by 7 to 3 days of taking hormone-free daily units.
  • the dosage form according to the invention preferably comprises at least 21, preferably 21 to 25, hormone-containing daily units which preferably include 5 to 30 ⁇ g of ethinyloestradiol and 0.5 to 5 mg of chlormadinone acetate, and 3 to 7 hormone-free daily units.
  • hormone-containing daily units preferably include 5 to 30 ⁇ g of ethinyloestradiol and 0.5 to 5 mg of chlormadinone acetate, and 3 to 7 hormone-free daily units.
  • the dosage form according to the invention may also comprise hormone-containing daily units for several years, preferably of 42 to 365 units, which contain the stated hormone combination in the stated ranges, wherein the corresponding uninterrupted tablet-taking periods are followed by 7 to 3 hormone-free daily units with an elevated amount of folic acid stated according to the invention.
  • the hormone-containing daily units of the dosage form according to the invention may take the form of a monophasic (one-phase) or multiphasic contraceptive.
  • a multiphasic contraceptive a two-phase or a three-phase pill may be present, which is not usually suitable, however, to be taken for a period longer than a woman's natural cycle.
  • the dosage form according to the invention may also be a constituent of a kit, wherein the kit according to the invention may comprise a plurality of the dosage forms according to the invention, especially if one dosage form comprises only one monthly cycle.
  • the kit may optionally include a calendar or a diary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, characterised in that the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women.

Description

  • The present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for uninterrupted daily oral administration to women, characterised in that the hormone-containing daily units contain folic acid in a daily amount of at most 200 μg and the hormone-free daily units in each case contain folic acid in a daily amount of >200 μg up to the maximum permissible amount of folic acid for women.
  • It is suspected that long-term taking of gestagen-based hormonal contraceptives may lead to a deficiency of folic acid. This deficiency may lead to cardiovascular diseases, for example.
  • It is also known that if pregnancy occurs a short time after stopping taking such hormonal contraceptives, there is a risk that the deficiency of folic acid may lead to neural tube defects in the embryo. Since the neural tube develops in the first weeks of pregnancy, it is particularly advantageous to ensure that folic acid is taken prior to conception.
  • If, therefore, a woman stops taking hormonal contraceptives because she wants to have a child and she falls pregnant in the first cycle after stopping the hormonal contraceptives, it is particularly important to ensure an appropriately high level of folic acid in the period directly after stopping taking the “Pill”, as hormonal contraceptives are known.
  • There is therefore a need to add folic acid to hormonal contraceptives in such a way that the added folic acid is adapted to a woman's varying needs over the period during and after a tablet-taking cycle.
  • The combination of hormonal contraceptives and folic acid is already known from WO 99/53910. The amount of folic acid per daily dose of hormones merely matches the changes in a woman's folic acid requirements as she ages, and does not take account of the changes in folic acid requirements over a contraceptive-taking cycle.
  • It was therefore the object of the present invention to provide a dosage form for hormonal contraception which takes account of the changes in folic acid requirements during a hormone-taking cycle and subsequent hormone-free daily units.
  • This object was achieved by providing the dosage form according to the invention for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for uninterrupted daily oral administration to women, characterised in that the hormone-containing daily units contain folic acid in a daily amount of at most 200 μg and the hormone-free daily units in each case contain folic acid in a daily amount of >200 μg up to the maximum permissible amount for women of folic acid.
  • Women of child-bearing age have a daily folic acid requirement which may be adequately met by a healthy diet. Long term taking of hormonal contraceptives containing gestagens may lead to an additional folic acid requirement, which may likewise be met by a healthy diet. However, it is advisable to provide women with a daily dose of the minimum effective daily amount of folic acid.
  • Accordingly, hormone-containing daily units of the dosage form according to the invention may each comprise a daily amount of folic acid corresponding to this minimum effective daily amount of folic acid. Preferably, the hormone-containing daily units of the dosage form according to the invention contain 0 to 200 μg of folic acid, particularly preferably 5 to 200 μg of folic acid.
  • The hormone-containing daily units of the dosage form according to the invention may also not contain any additional folic acid, however.
  • To ensure that a woman consumes the necessary amount of folic acid or that her increased folic acid requirement at least at the beginning of pregnancy is met as quickly as possible if she decides to try for a baby, so avoiding possible damage to the embryo due to a folic acid deficiency, the hormone-free daily units of the folic acid dosage form according to the invention contain folic acid in an amount of more than 200 μg up to the maximum permissible daily amount of folic acid for women, preferably up to 5 mg of folic acid per daily unit, particularly preferably of more than 200 μg to 5 mg folic acid, very particularly preferably up to the maximum permissible daily amount of folic acid for women of reproductive age.
  • By adding folic acid to the hormone-free daily units of the dosage form according to the invention in amounts of up to the maximum permissible amount, it is possible to increase the folic acid concentration in a woman's body while she is taking the hormone-free daily units to the extent that the her body's increased folic acid requirement is met as quickly as possible if she stops taking a hormone-containing contraceptive and then falls pregnant.
  • The hormone-containing daily units of the dosage form according to the invention preferably each contain the same amount of folic acid. This also applies to the hormone-free daily units, which likewise each contain the same amount of folic acid, this being greater than the amount contained in the hormone-containing daily units however.
  • The folic acid may also be present in the dosage form according to the invention as a pharmaceutically safe salt, preferably as sodium, potassium or magnesium salt, or as a corresponding derivative.
  • Suitable derivatives of folic acid are mono- or diesters, wherein the diesters may be differently or identically esterified. Suitable ester groups are preferably C1-C8 low alkyl groups, such as methyl, ethyl, propyl or butyl, branched C1-C8 low alkyl groups, such as isopropyl, isobutyl or sec.-butyl, cycloalkyl groups, such as cyclopentyl or cyclohexyl, aryl groups, such as phenyl or substituted phenyl with 1-2 substituents, such as low alkyl or haloalkoxyl groups, or arylalkyl groups with C1-C8 alkyl and aryl groups, such as phenyl or substituted phenyl.
  • In addition, the hormone-free daily units and optionally the hormone-containing daily units may contain further vitamins or minerals in addition to the folic acid.
  • The number of daily units of a dosage form according to the invention may correspond to a natural, monthly menstrual cycle. In this case, the dosage form according to the invention contains 21 to 25 hormone-containing daily units and 7 to 3 hormone-free daily units.
  • However, it is also possible for the total number of hormone-containing daily units to correspond to more than a woman's natural monthly cycle, such that a dosage form according to the invention may contain hormone-containing daily units to be taken without interruption for up to 2 years, preferably up to 1 year, and 7 to 3 hormone-free daily units. However, it is also possible for the dosage form according to the invention to comprise 42 to 52 or 77 to 193 hormone-containing daily units alongside 7 to 3 hormone-free daily units.
  • The hormone-containing daily units of the dosage form according to the invention may each contain at least one contraceptively acting hormone component, preferably a combination of hormone components such as an oestrogen and a gestagen.
  • Oestrogens which are suitable for the hormone-containing daily units of the dosage form according to the invention are preferably selected from the group comprising oestradiol, oestradiol valerate, ethinyloestradiol and mestranol. Ethinyloestradiol is particularly preferred as the oestrogen for the dosage form according to the invention.
  • Gestagens which are suitable for the hormone-containing daily units of the dosage form according to the invention are preferably selected from the group comprising norethisterone, norethisterone acetate, norethisterone enantate, norgestimate, norgestrel, levonorgestrel, gestodene, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, lynestrenol, cyproterone acetate, drospirenone, dienogest, desogestrel, progesterone, dydrogesterone, medrogestone, ethynodiol, promegestone, nomegestrol acetate and trimegestone.
  • The hormones are preferably used in the amounts stated below.
    Oestrogens:
    Oestradiol, oestradiol valerate 0.5 to 4 mg
    Ethinyloestradiol 5 to 50 μg
    Mestranol 8 to 70 μg
  • Gestagens:
    Norethisterone, norethisterone acetate 0.5 to 1.0 mg
    Norgestimate 0.1 to 0.25 mg
    Norgestrel 0.3 to 1.0 mg
    Levonorgestrel 0.05 to 0.15 mg
    Gestodene 0.05 to 0.12 mg
    Hydroxyprogesterone caproate 10 to 800 mg
    Medroxyprogesterone acetate 2.5 to 40 mg
    Megestrol acetate 1.0 to 10 mg
    Chlormadinone acetate 0.5 to 10 mg
    Lynestrenol 0.4 to 3 mg
    Cyproterone acetate 0.5 to 10 mg
    Drospirenone 1.0 to 10 mg
    Dienogest 1.0 to 10 mg
    Desogestrel 0.06 to 0.30 mg
    Progesterone 100 to 1000 mg
    Dydrogesterone 5 to 50 mg
    Medrogestone 2 to 30 mg
    Ethynodiol, ethynodiol diacetate 0.4 to 3 mg
    Promegestone 0.5 to 10 mg
    Nomegestrol acetate 0.5 to 10 mg
    Trimegestone 1 to 10 mg
    Etonogestrel 0.1 to 1 mg
    Norelgestromin 0.1 to 2 mg
    Norethynodrel 0.3 to 3 mg
    Tibolone 1 to 10 mg
  • The dosage forms according to the invention, especially the hormone-containing daily units, preferably comprise the following hormone combinations:
      • 1. 0.015 mg ethinyloestradiol+0.06 mg gestodene
      • 2. 0.02 mg ethinyloestradiol+0.15 mg desogestrel
      • 3. 0.02 mg ethinyloestradiol+0.5 mg norethisterone
      • 4. 0.02 mg ethinyloestradiol+1 mg chlormadinone acetate or 2 mg or 3 mg chlormadinone acetate
      • 5. 0.02 mg ethinyloestradiol+1 mg norethisterone
      • 6. 0.03 mg ethinyloestradiol+1 mg norethisterone
      • 7. 0.02 mg ethinyloestradiol+4 mg chlormadinone acetate
      • 8. 0.02 mg ethinyloestradiol+5 mg chlormadinone acetate
      • 9. 0.02 mg ethinyloestradiol+0.1 mg levonorgestrel
      • 10. 0.02 mg ethinyloestradiol+0.15 mg desogestrel
      • 11. 0.02 mg ethinyloestradiol+0.1 mg levonorgestrel
      • 12. 0.03 mg ethinyloestradiol+3 mg drospirenone
      • 13. 0.02 mg ethinyloestradiol+3 mg drospirenone
      • 14. 0.03 mg ethinyloestradiol+2 mg chlormadinone acetate
      • 15. 0.035 mg ethinyloestradiol+0.25 mg norgestimate
      • 16. 0.03 mg ethinyloestradiol+0.5 mg norethisterone
      • 17. 0.03 mg ethinyloestradiol+0.15 mg desogestrel
      • 18. 0.03 mg ethinyloestradiol+0.075 mg gestodene
      • 19. 0.03 mg ethinyloestradiol+0.15 mg levonorgestrel
      • 20. 0.03 mg ethinyloestradiol+0.15 mg desogestrel
      • 21. 0.03 mg ethinyloestradiol+0.15 mg levonorgestrel
      • 22. 0.03 mg ethinyloestradiol+0.125 mg levonorgestrel
      • 23. 0.0375 mg ethinyloestradiol+0.75 mg lynestrenol
      • 24. 0.03 mg ethinyloestradiol+1 mg norethisterone
      • 25. 0.03 mg ethinyloestradiol+0.5 mg norethisterone
      • 26. 0.03 mg ethinyloestradiol+0.15 mg levonorgestrel
      • 27. 0.04 mg ethinyloestradiol+2 mg lynestrenol
      • 28. 1 st phase=7 days
        • 0.050 mg desogestrel+0.035 ethinyloestradiol
        • 2nd phase=7 days
        • 0.100 mg desogestrel+0.030 ethinyloestradiol
        • 3rd phase=7 days
        • 0.150 mg desogestrel+0.030 ethinyloestradiol
      • 29. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=10 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 30. 1 st phase=7 days
        • 0.035 mg EE+0.180 mg norgestimate
        • 2nd phase=7 days
        • 0.035 mg EE+0.215 mg norgestimate
        • 3rd phase=7 days
        • 0.035 mg EE+0.250 mg norgestimate
      • 31. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=10 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 32. 1 st phase=7 days
        • 0.035 mg EE+0.5 mg norethisterone
        • 2nd phase=9 days
        • 0.035 mg EE+1 mg norethisterone
        • 3rd phase=5 days
        • 0.035 mg EE+0.5 mg norethisterone
      • 33. 1st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=10 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 34. 1 st phase=7 days
        • 0.035 mg EE+0.5 mg norethisterone
        • 2nd phase=7 days
        • 0.035 mg EE+0.75 mg norethisterone
        • 3rd phase=7 days
        • 0.035 mg EE+1 mg norethisterone
      • 35. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=10 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 36. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=6 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=9 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 37. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.05 mg EE+0.05 mg levonorgestrel
        • 3rd phase=10 days
        • 0.04 mg EE+0.125 mg levonorgestrel
      • 38. 1 st phase=6 days
        • 0.03 mg EE+0.05 mg levonorgestrel
        • 2nd phase=5 days
        • 0.04 mg EE+0.075 mg levonorgestrel
        • 3rd phase=10 days
        • 0.03 mg EE+0.125 mg levonorgestrel
      • 39. 0.035 mg ethinyloestradiol+2 mg cyproterone acetate
      • 40. 0.05 mg mestranol+2 mg chlormadinone acetate
      • 41. 1 st phase=11 days
        • 0.05 mg ethinyloestradiol+1 mg chlormadinone acetate
        • 2nd phase=11 days
        • 0.05 mg ethinyloestradiol+2 mg chlormadinone acetate
      • 42. 0.08 mg mestranol+2 mg chlormadinone acetate
      • 43. 0.03 mg ethinyloestradiol+2 mg dienogest
      • 44. 0.05 mg ethinyloestradiol+0.5 mg norgestrel
      • 45. 0.05 mg ethinyloestradiol+0.125 mg levonorgestrel
      • 46. 0.05 mg ethinyloestradiol+0.25 mg levonorgestrel
      • 47. 0.05 mg ethinyloestradiol+0.125 mg levonorgestrel
      • 48. 0.05 mg ethinyloestradiol+1 mg norethisterone acetate
      • 49. 0.05 mg ethinyloestradiol+0.25 mg levonorgestrel
      • 50. 1 st phase=7 days
        • 0.04 mg ethinyloestradiol+0.025 mg desogestrel
        • 2nd phase=15 days
        • 0.03 mg ethinyloestradiol+0.125 mg desogestrel
      • 51. 1 st phase=11 days
        • 0.05 mg ethinyloestradiol+0.05 mg levonorgestrel
        • 2nd phase=10 days
        • 0.05 mg ethinyloestradiol+0.125 mg levonorgestrel
      • 52. 1 st phase=11 days
        • 0.05 mg ethinyloestradiol+0.05 mg levonorgestrel
        • 2nd phase=10 days
        • 0.05 mg ethinyloestradiol+0.125 mg levonorgestrel
      • 53. 1 st phase=7 days
        • 0.05 mg ethinyloestradiol+2nd phase=15 days
        • 0.05 mg ethinyloestradiol+2.5 mg lynestrenol
      • 54. 1 st phase=7 days
        • 0.05 mg ethinyloestradiol+2nd phase=15 days
        • 0.05 mg ethinyloestradiol+0.125 mg desogestrel
      • 55. 1 st phase=6 days
        • 0.05 mg ethinyloestradiol+2nd phase=15 days
        • 0.05 mg ethinyloestradiol+1 mg norethisterone acetate
  • Where the dosage form according to the invention provides a multiphasic hormone combination, it is recommended that the hormone-containing daily units be taken without interruption only for a period of 21 to 25 days, followed by 7 to 3 days of taking hormone-free daily units.
  • The dosage form according to the invention preferably comprises at least 21, preferably 21 to 25, hormone-containing daily units which preferably include 5 to 30 μg of ethinyloestradiol and 0.5 to 5 mg of chlormadinone acetate, and 3 to 7 hormone-free daily units. However, the dosage form according to the invention may also comprise hormone-containing daily units for several years, preferably of 42 to 365 units, which contain the stated hormone combination in the stated ranges, wherein the corresponding uninterrupted tablet-taking periods are followed by 7 to 3 hormone-free daily units with an elevated amount of folic acid stated according to the invention.
  • As already stated, the hormone-containing daily units of the dosage form according to the invention may take the form of a monophasic (one-phase) or multiphasic contraceptive. In the case of a multiphasic contraceptive, a two-phase or a three-phase pill may be present, which is not usually suitable, however, to be taken for a period longer than a woman's natural cycle.
  • The dosage form according to the invention may also be a constituent of a kit, wherein the kit according to the invention may comprise a plurality of the dosage forms according to the invention, especially if one dosage form comprises only one monthly cycle. The kit may optionally include a calendar or a diary.

Claims (16)

1. A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for uninterrupted daily oral administration to women, characterised in that the hormone-containing daily units contain folic acid in a daily amount of at most 200 μg and the hormone-free daily units in each case contain folic acid in a daily amount of >200 μg up to the maximum permissible amount for women of folic acid:
2. A dosage form according to claim 1, characterised in that the hormone-containing daily units each contain 5 to 200 μg of folic acid.
3. A dosage form according to claim 1, characterised in that the hormone-containing daily units do not contain any folic acid.
4. A dosage form according to claim 1, characterised in that the hormone-containing daily units contain folic acid in an amount up to the minimum effective daily amount for women.
5. A dosage form according to claim 1, characterised in that the hormone-free daily units each contain more than 200 μg and up to 5 mg.
6. A dosage form according to claim 1, characterised in that the hormone-containing daily units each contain the same amount of folic acid and the hormone-free daily units likewise each contain the same amount of folic acid.
7. A dosage form according to claim 1, characterised in that it comprises at least 21 hormone-containing daily units and 7 to 3 hormone-free daily units.
8. A dosage form according to claim 7, characterised in that its maximum number of hormone-containing daily units is sufficient for administration for several years, preferably for 2 years, particularly preferably for 1 year, and the number of hormone-free daily units corresponds to 7 to 3 days.
9. A dosage form according to claim 7, characterised in that it comprises up to 730, preferably up to 365, hormone-containing daily units and 7 to 3 hormone-free daily units.
10. A dosage form according to claim 7, characterised in that it comprises 21 to 25 hormone-containing daily units and 7 to 3 hormone-free daily units.
11. A dosage form according to claim 7, characterised in that it comprises 42 to 52 hormone-containing daily units and 7 to 3 hormone-free daily units.
12. A dosage form according to claim 7, characterised in that it comprises 77 to 193 hormone-containing daily units and 7 to 3 hormone-free daily units.
13. A dosage form according to claim 1, characterised in that the hormone-containing daily units each contain at least one contraceptively active hormone component, preferably a combination of hormone components, particularly preferably a combination of an oestrogen and a gestagen.
14. A dosage form according to claim 1, characterised in that the number of hormone-containing daily units corresponds to a monophasic contraceptive.
15. A kit containing at least one dosage form for hormonal contraception according to claim 1.
16. A kit according to claim 15, characterised in that it contains a plurality of dosage forms according to claim 1 any one of 1.
US11/009,817 2004-05-28 2004-12-10 Dosage form for hormonal contraception Abandoned US20050267083A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/244,974 US8580771B2 (en) 2004-05-28 2005-10-06 Dosage form for hormonal contraception
US13/070,205 US20110172197A1 (en) 2004-05-28 2011-03-23 Dosace Form For Hormonal Contraceptive

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004026671A DE102004026671A1 (en) 2004-05-28 2004-05-28 Dosage form for hormonal contraception
DE102004026671.9 2004-05-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/009,938 Continuation-In-Part US9278072B2 (en) 2004-05-28 2004-12-10 Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/244,974 Continuation-In-Part US8580771B2 (en) 2004-05-28 2005-10-06 Dosage form for hormonal contraception

Publications (1)

Publication Number Publication Date
US20050267083A1 true US20050267083A1 (en) 2005-12-01

Family

ID=35456153

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/009,817 Abandoned US20050267083A1 (en) 2004-05-28 2004-12-10 Dosage form for hormonal contraception
US11/244,974 Active 2030-09-08 US8580771B2 (en) 2004-05-28 2005-10-06 Dosage form for hormonal contraception
US13/070,205 Abandoned US20110172197A1 (en) 2004-05-28 2011-03-23 Dosace Form For Hormonal Contraceptive

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/244,974 Active 2030-09-08 US8580771B2 (en) 2004-05-28 2005-10-06 Dosage form for hormonal contraception
US13/070,205 Abandoned US20110172197A1 (en) 2004-05-28 2011-03-23 Dosace Form For Hormonal Contraceptive

Country Status (2)

Country Link
US (3) US20050267083A1 (en)
DE (1) DE102004026671A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080261934A1 (en) * 2005-11-09 2008-10-23 Gruenenthal Gmbh Dosage Form for Hormonal Contraception
US20090254132A1 (en) * 2005-07-07 2009-10-08 Scribner Robert M Devices and methods for the treatment of bone fracture

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Dosage form for hormonal contraception
DE102005034498A1 (en) * 2005-07-20 2007-01-25 Grünenthal GmbH Oral contraception with Trimegeston
BRPI0713999A2 (en) * 2006-07-06 2012-11-20 Bayer Schering Pharma Ag pharmaceutical production for contraception and risk reduction of congenital malformations
AT12800U1 (en) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag A pharmaceutical preparation for use in the oral contraception of lactose intolerant women

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
US6312722B1 (en) * 1995-06-28 2001-11-06 Schering Aktiengesellschaft Pharmaceutical combined preparation, kit and method for hormonal contraception
US6500814B1 (en) * 1997-09-11 2002-12-31 Wyeth Pharmaceuticals Hormonal contraceptive

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4635051A (en) 1983-09-26 1987-01-06 Tektronix, Inc. High-speed electro-optical light gate and field sequential full color display system incorporating same
AU4805085A (en) 1984-09-05 1986-03-24 Schering Aktiengesellschaft Mittel zur behandlung von androgenisierungserscheinungen und verwendung von antiandrogenen zur herstellung des mittels
DK174724B1 (en) 1986-07-15 2003-10-06 Wyeth Corp Use of a composition comprising an estrogen and a progestogen for the preparation of a dosage form to provide hormone replacement therapy and contraception for women during the premenopause and pack to provide the composition
DE3916112A1 (en) 1989-05-16 1990-11-22 Schering Ag DIHYDROSPIRORENONE AS AN ANTIANDROGEN
DE4104385C1 (en) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4321957C2 (en) 1993-07-01 1995-09-28 Marika Dr Med Ehrlich Use of a hormonal agent to treat acne
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19705229C2 (en) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Use of three hormonal components for hormonal contraception for the treatment and / or prophylaxis of tumors of the mammary glands
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
HUP9900213A1 (en) * 1999-02-01 2000-12-28 Gábor Bogye Pharmaceutical compositions for diminishing side-effects of gestagene-type hormone-containing compositions
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
DE10045380A1 (en) 2000-09-14 2002-04-04 Schering Ag Contraception procedure and dosage form
PT1390040E (en) 2001-05-18 2007-04-30 Pantarhei Bioscience Bv Pharmaceutical composition for use in hormone replacement therapy
ATE254465T1 (en) * 2001-05-23 2003-12-15 Pantarhei Bioscience Bv PREPARATIONS FOR HORMONAL CONTRACEPTION
US6911438B2 (en) * 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation
CA2494687A1 (en) 2002-08-15 2004-02-26 Wyeth Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
DE102004026669A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Use of a combination of ethinylestradiol and chlormadinone acetate for the manufacture of a medicament
DE102004026679A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
DE102004026670A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate
DE102004026671A1 (en) * 2004-05-28 2005-12-15 Grünenthal GmbH Dosage form for hormonal contraception
DE102005034498A1 (en) * 2005-07-20 2007-01-25 Grünenthal GmbH Oral contraception with Trimegeston

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312722B1 (en) * 1995-06-28 2001-11-06 Schering Aktiengesellschaft Pharmaceutical combined preparation, kit and method for hormonal contraception
US6500814B1 (en) * 1997-09-11 2002-12-31 Wyeth Pharmaceuticals Hormonal contraceptive
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090254132A1 (en) * 2005-07-07 2009-10-08 Scribner Robert M Devices and methods for the treatment of bone fracture
US20080261934A1 (en) * 2005-11-09 2008-10-23 Gruenenthal Gmbh Dosage Form for Hormonal Contraception
US8119620B2 (en) 2005-11-09 2012-02-21 Gruenenthal Gmbh Dosage form for hormonal contraception

Also Published As

Publication number Publication date
US8580771B2 (en) 2013-11-12
US20060089338A1 (en) 2006-04-27
US20110172197A1 (en) 2011-07-14
DE102004026671A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US20050113350A1 (en) Extended use combination comprising estrogens and progestins
US20080234240A1 (en) Extended Use Combination Comprising Estrogens And Progestins
EP0717626B1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
US8119620B2 (en) Dosage form for hormonal contraception
CA2179728A1 (en) Composition for a contraceptive comprising an estrogen and a gestagen
US20100168071A1 (en) Extended estrogen dosing contraceptive regimen
RU98101254A (en) PHARMACEUTICAL COMBINED DRUG, TOOL KIT AND HORMONAL CONTRACEPTION METHOD
US20110172197A1 (en) Dosace Form For Hormonal Contraceptive
US20040242550A1 (en) Means and method for hormonal contraception
ES2438734T3 (en) Contraceptive containing folic acid
US20050064031A1 (en) Combination contraceptive, kits that contain the latter, and a method that uses the latter
EP1286666B1 (en) Starter kit for low dose oral contraceptives
CA2392841A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US20040198707A1 (en) Means and method for hormonal contraception
US20040202713A1 (en) Means and method for hormonal contraception
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
CA2171460C (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
CA2624380A1 (en) Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding
MXPA06006031A (en) Extended use combination comprising estrogens and progestins

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUNENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHRAMM, GEORG;PAQUES, ERIC-PAUL;REEL/FRAME:016498/0897

Effective date: 20050331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION